Cargando…

Evaluation of an ADVanced Organ Support (ADVOS) system in a two-hit porcine model of liver failure plus endotoxemia

BACKGROUND: Novel extracorporeal procedures are constantly being developed and evaluated for use in patients with sepsis. Preclinical evaluation of such procedures usually requires testing in large animal models. In the present work, the safety and efficacy of a recently developed ADVanced Organ Sup...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Chalabi, Ahmed, Matevossian, Edouard, von Thaden, Anne, Schreiber, Catherine, Radermacher, Peter, Huber, Wolfgang, Perez Ruiz de Garibay, Aritz, Kreymann, Bernhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496922/
https://www.ncbi.nlm.nih.gov/pubmed/28677045
http://dx.doi.org/10.1186/s40635-017-0144-3
_version_ 1783248064456163328
author Al-Chalabi, Ahmed
Matevossian, Edouard
von Thaden, Anne
Schreiber, Catherine
Radermacher, Peter
Huber, Wolfgang
Perez Ruiz de Garibay, Aritz
Kreymann, Bernhard
author_facet Al-Chalabi, Ahmed
Matevossian, Edouard
von Thaden, Anne
Schreiber, Catherine
Radermacher, Peter
Huber, Wolfgang
Perez Ruiz de Garibay, Aritz
Kreymann, Bernhard
author_sort Al-Chalabi, Ahmed
collection PubMed
description BACKGROUND: Novel extracorporeal procedures are constantly being developed and evaluated for use in patients with sepsis. Preclinical evaluation of such procedures usually requires testing in large animal models. In the present work, the safety and efficacy of a recently developed ADVanced Organ Support (ADVOS) system in a newly developed large animal two-hit model of liver failure combined with endotoxemia were tested. METHODS: After establishing the model in more than 50 animals, a randomized study was performed. An inflammatory cholestatic liver injury was initially provoked in pigs. Three days after surgery, endotoxin was gradually administered during 7½ h. Animals were randomized to receive standard medical treatment either with (ADVOS group, n = 5) or without ADVOS (control group, n = 5). The ADVOS treatment was started 2½ h after endotoxemia and continued for 7 h. Survival, cardiovascular, respiratory, renal, liver, coagulation, and cerebral parameters were analyzed. RESULTS: Three days after surgery, cholestatic injury resulted in hyperbilirubinemia [5.0 mg/dl (IQR 4.3–5.9 mg/dl)], hyperammonemia [292 μg/dl (IQR 291–296 μg/dl)], leukocytosis [20.2 10(3)/μl (IQR 17.7–21.8 10(3)/μl)], and hyperfibrinogenemia [713 mg/dl (IQR 654–803 mg/dl)]. After endotoxemia, the ADVOS procedure stabilized cardiovascular, respiratory, and renal parameters and eliminated surrogate markers as bilirubin [2.3 (IQR 2.3–3.0) vs. 5.5 (IQR 4.6–5.6) mg/dl, p = 0.001] and creatinine [1.4 (IQR 1.1–1.7) vs. 2.3 (IQR 2.1–3.1) mg/dl, p = 0.01]. Mortality: All animals in the ADVOS group survived, while all animals in the control group expired during the 10-h observation period (p = 0.002). No adverse events related to the procedure were observed. CONCLUSIONS: The ADVOS procedure showed a promising safety and efficacy profile and improved survival in a sepsis-like animal model with dysfunction of multiple organs. An amelioration of major organ functions (heart and lung) combined with removal of markers for kidney and liver function was observed. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40635-017-0144-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5496922
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-54969222017-07-20 Evaluation of an ADVanced Organ Support (ADVOS) system in a two-hit porcine model of liver failure plus endotoxemia Al-Chalabi, Ahmed Matevossian, Edouard von Thaden, Anne Schreiber, Catherine Radermacher, Peter Huber, Wolfgang Perez Ruiz de Garibay, Aritz Kreymann, Bernhard Intensive Care Med Exp Research BACKGROUND: Novel extracorporeal procedures are constantly being developed and evaluated for use in patients with sepsis. Preclinical evaluation of such procedures usually requires testing in large animal models. In the present work, the safety and efficacy of a recently developed ADVanced Organ Support (ADVOS) system in a newly developed large animal two-hit model of liver failure combined with endotoxemia were tested. METHODS: After establishing the model in more than 50 animals, a randomized study was performed. An inflammatory cholestatic liver injury was initially provoked in pigs. Three days after surgery, endotoxin was gradually administered during 7½ h. Animals were randomized to receive standard medical treatment either with (ADVOS group, n = 5) or without ADVOS (control group, n = 5). The ADVOS treatment was started 2½ h after endotoxemia and continued for 7 h. Survival, cardiovascular, respiratory, renal, liver, coagulation, and cerebral parameters were analyzed. RESULTS: Three days after surgery, cholestatic injury resulted in hyperbilirubinemia [5.0 mg/dl (IQR 4.3–5.9 mg/dl)], hyperammonemia [292 μg/dl (IQR 291–296 μg/dl)], leukocytosis [20.2 10(3)/μl (IQR 17.7–21.8 10(3)/μl)], and hyperfibrinogenemia [713 mg/dl (IQR 654–803 mg/dl)]. After endotoxemia, the ADVOS procedure stabilized cardiovascular, respiratory, and renal parameters and eliminated surrogate markers as bilirubin [2.3 (IQR 2.3–3.0) vs. 5.5 (IQR 4.6–5.6) mg/dl, p = 0.001] and creatinine [1.4 (IQR 1.1–1.7) vs. 2.3 (IQR 2.1–3.1) mg/dl, p = 0.01]. Mortality: All animals in the ADVOS group survived, while all animals in the control group expired during the 10-h observation period (p = 0.002). No adverse events related to the procedure were observed. CONCLUSIONS: The ADVOS procedure showed a promising safety and efficacy profile and improved survival in a sepsis-like animal model with dysfunction of multiple organs. An amelioration of major organ functions (heart and lung) combined with removal of markers for kidney and liver function was observed. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40635-017-0144-3) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-07-04 /pmc/articles/PMC5496922/ /pubmed/28677045 http://dx.doi.org/10.1186/s40635-017-0144-3 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Al-Chalabi, Ahmed
Matevossian, Edouard
von Thaden, Anne
Schreiber, Catherine
Radermacher, Peter
Huber, Wolfgang
Perez Ruiz de Garibay, Aritz
Kreymann, Bernhard
Evaluation of an ADVanced Organ Support (ADVOS) system in a two-hit porcine model of liver failure plus endotoxemia
title Evaluation of an ADVanced Organ Support (ADVOS) system in a two-hit porcine model of liver failure plus endotoxemia
title_full Evaluation of an ADVanced Organ Support (ADVOS) system in a two-hit porcine model of liver failure plus endotoxemia
title_fullStr Evaluation of an ADVanced Organ Support (ADVOS) system in a two-hit porcine model of liver failure plus endotoxemia
title_full_unstemmed Evaluation of an ADVanced Organ Support (ADVOS) system in a two-hit porcine model of liver failure plus endotoxemia
title_short Evaluation of an ADVanced Organ Support (ADVOS) system in a two-hit porcine model of liver failure plus endotoxemia
title_sort evaluation of an advanced organ support (advos) system in a two-hit porcine model of liver failure plus endotoxemia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496922/
https://www.ncbi.nlm.nih.gov/pubmed/28677045
http://dx.doi.org/10.1186/s40635-017-0144-3
work_keys_str_mv AT alchalabiahmed evaluationofanadvancedorgansupportadvossysteminatwohitporcinemodelofliverfailureplusendotoxemia
AT matevossianedouard evaluationofanadvancedorgansupportadvossysteminatwohitporcinemodelofliverfailureplusendotoxemia
AT vonthadenanne evaluationofanadvancedorgansupportadvossysteminatwohitporcinemodelofliverfailureplusendotoxemia
AT schreibercatherine evaluationofanadvancedorgansupportadvossysteminatwohitporcinemodelofliverfailureplusendotoxemia
AT radermacherpeter evaluationofanadvancedorgansupportadvossysteminatwohitporcinemodelofliverfailureplusendotoxemia
AT huberwolfgang evaluationofanadvancedorgansupportadvossysteminatwohitporcinemodelofliverfailureplusendotoxemia
AT perezruizdegaribayaritz evaluationofanadvancedorgansupportadvossysteminatwohitporcinemodelofliverfailureplusendotoxemia
AT kreymannbernhard evaluationofanadvancedorgansupportadvossysteminatwohitporcinemodelofliverfailureplusendotoxemia